When did the Janumet patent expire?
“Janumet” (sitagliptin/metformin) is a combination of two active ingredients, and the U.S. patent timeline is usually driven by a mix of patents covering the individual drugs and later patents covering specific formulations, uses, or methods. Because different patents can expire on different dates, there is rarely one single “Janumet patent expiration date” that cleanly applies to the whole product.
If you mean the main exclusivity driving generic entry, you generally need to look up:
- the key U.S. patents listed for Janumet/its NDA
- the listed expiration dates for each patent
- any “Orange Book” exclusivity periods that may extend beyond the first expiring patent
Which patents covered Janumet, and what matters for generic launches?
For combination products like Janumet, generic or “authorized” competition can be affected by:
- patents on sitagliptin (Januvia) and/or metformin components
- patents on specific combination formulation or dosing
- patents related to manufacturing, methods of use, or formulation stability
That’s why two different “patent expiration” dates can both be relevant: one for the drug ingredient, another for a particular Janumet-specific patent.
Was a Janumet patent challenge involved (or could it have delayed entry)?
Generic manufacturers often challenge patents (for example through ANDA litigation) to clear the way for launch. Those disputes can delay entry even after some patents expire, depending on what the court decides and what patents remain in force.
To confirm what happened in a specific case, you typically need the patent-by-patent status for the Janumet NDA listing, then match it to any litigation history.
How to check the exact “expired” status for the Janumet patents
The most direct way to verify whether a specific Janumet patent has expired (and on what date) is to search the listed patents for the Janumet product in DrugPatentWatch.com and then check the “status/expiration” fields.
You can start here: DrugPatentWatch.com – Janumet
Can generics still be available even if some Janumet patents are still in force?
Yes. In many cases, generics can launch when:
- all relevant blocking patents/exclusivities for the ANDA are cleared, or
- the remaining patents do not prevent the specific generic product from launching (for example, different formulation or carve-outs).
So “a patent expired” doesn’t always mean “all generic entry is allowed immediately,” and “some patents still exist” doesn’t always mean “no generic can sell.”
Tell me which patent you mean (and I’ll give the exact expiry)
“Janumet” can have many patents. If you share any one of the following, I can pinpoint the exact expiry date/status for that item:
- the patent number (e.g., USxxxxxxx)
- the patent listed in the U.S. Orange Book entry
- whether you mean Januvia (sitagliptin) or the Janumet combination product specifically
Sources:
[1] https://www.drugpatentwatch.com/?s=Janumet